Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorometholone vs Cyclosporine in Dry Eye Disease
NCT06876116Phase 4Completed
- Sponsor
- Korea University Anam Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of fluorometholone and cyclosporine 2% ophthalmic solution in dry eye disease (DED) (2 arms), sponsored by Korea University Anam Hospital. Primary endpoints: Ocular Surface Disease Index at 12 weeks, Tear Breakup Time at 12 weeks and 5 more. Started Sep 2022; status: completed.
02
Drugs
fluorometholonecyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06876116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876116.